Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.91 |
| ▸ | ITGB3 | P05106 | 19/20 | 0.91 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.66 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.61 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.61 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.53 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6424346 | 1.00 | ITGAV (0.91) | ITGAVITGB3ITGA2BITGB1ITGA4 | |
| Trifluoroacetic Acid SCHEMBL6466536 | 0.91 | ITGB3 (0.76) | ITGAVITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL6424349 | 0.90 | ITGB3 (0.78) | ITGAVITGB3ITGA2BITGB1ITGA4 | |
| Trifluoroacetic Acid SCHEMBL6424123 | 0.89 | ITGAV (0.72) | ITGAVITGB3ITGA2BITGB1ITGA4 | |
| Trifluoroacetic Acid SCHEMBL6424127 | 0.89 | ITGAV (0.72) | ITGAVITGB3ITGA2BITGB1ITGA4 | |
| Trifluoroacetic Acid SCHEMBL6423286 | 0.85 | ITGAV (0.70) | ITGAVITGB3ITGA2BITGB1ITGB6 | |
| SCHEMBL6421817 | 0.84 | ITGAV (0.81) | ITGAVITGB3ITGB1ITGA4ITGB6 | |
| SCHEMBL6421825 | 0.84 | ITGAV (0.81) | ITGAVITGB3ITGB1ITGA4ITGB6 | |
| SCHEMBL6422753 | 0.83 | ITGAV (1.00) | ITGAVITGB3ITGA2BITGB6 | |
| SCHEMBL6422836 | 0.83 | ITGAV (1.00) | ITGAVITGB3ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | claimed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | claimed |
| EP-1040098-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-10-04 | — | — | EP | claimed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | claimed |
| WO-1999031061-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | claimed |
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6784190-B2 | USEFUL FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, TUMOR, ATHEROSCLEROSIS, INFLAMMATION, WOUND HEALING, VIRAL DISEASEDISEASE, TUMOR | MERCK & CO., INC. | 2004-08-31 | — | — | US | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1040098-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| WO-1999031061-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | ITGAV 1/4885ITGB3 2/4885ITGA2B 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.